sofpironium

Sofpironium is a **topical anticholinergic small molecule** developed by Botanix and previously by Brickell Biotech for the treatment of **primary axillary hyperhidrosis**. Its active moiety is sofpironium bromide, formulated as a topical gel, and it is marketed as **Sofdra** in the United States and **Ecclock** in Japan. Sofpironium is a retrometabolically designed anticholinergic that inhibits **muscarinic acetylcholine receptors, particularly the M3 receptor on eccrine sweat glands**, thereby reducing sweat production in the axillae. The compound undergoes rapid nonenzymatic hydrolysis, which is intended to limit systemic exposure and reduce anticholinergic adverse effects while maintaining local efficacy.

Brand names

SofdraEcclock

Other names

sofpironium bromide